Clonidine Pharmacokinetics in Pregnancy

被引:44
作者
Buchanan, M. L. [1 ]
Easterling, T. R. [2 ]
Carr, D. B. [2 ]
Shen, D. D. [1 ,4 ]
Risler, L. J. [4 ]
Nelson, W. L. [3 ]
Mattison, D. R. [5 ]
Hebert, M. F. [1 ,2 ]
机构
[1] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[2] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA
[4] Fred Hutchinson Canc Res Ctr, Pharmacokinet Lab, Seattle, WA 98104 USA
[5] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA
关键词
CYP3A;
D O I
10.1124/dmd.108.024984
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this study was to determine the pharmacokinetic parameters of clonidine during pregnancy compared with previously published data in nonpregnant subjects. Serial blood and urine samples were collected in 17 women during mid to late pregnancy over one steady-state dosing interval to determine clonidine noncompartmental pharmacokinetic parameters (n = 17) and creatinine clearance. In six of these pregnant subjects, maternal and umbilical cord (venous and arterial) plasma samples were collected at the time of delivery for measurement of clonidine concentrations. Clonidine apparent oral clearance was found to be 440 +/- 168 ml/min during pregnancy compared with 245 +/- 72 ml/min as previously reported in nonpregnant subjects (p < 0.0001) (Cunningham et al., 1994). There was a strong correlation (r = 0.82, p < 0.001) between clonidine renal clearance, adjusted for variation in glomerular filtration rate, and urine pH. Umbilical cord to maternal plasma clonidine concentration ratios were 1.0 +/- 0.1 (arterial) and 1.0 +/- 0.1 (venous). In conclusion, clonidine is cleared more rapidly in pregnant women than in nonpregnant subjects. At the time of delivery, the fetus is exposed to similar plasma clonidine concentrations as the mother.
引用
收藏
页码:702 / 705
页数:4
相关论文
共 17 条
[1]   NEW ASPECTS OF THE CLINICAL-PHARMACOLOGY OF CLONIDINE [J].
ARNDTS, D .
CHEST, 1983, 83 (02) :397-400
[2]  
ARNDTS D, 1979, ARZNEIMITTEL-FORSCH, V29-1, P532
[3]  
BOUTROY MJ, 1988, EARLY HUM DEV, V17, P275, DOI 10.1016/S0378-3782(88)80014-8
[4]   COMPARATIVE PHARMACOKINETICS OF ORAL VERSUS SUBLINGUAL CLONIDINE [J].
CUNNINGHAM, FE ;
BAUGHMAN, VL ;
PETERS, J ;
LAURITO, CE .
JOURNAL OF CLINICAL ANESTHESIA, 1994, 6 (05) :430-433
[5]  
DARDA S, 1978, ARZNEIMITTEL-FORSCH, V28-1, P255
[6]  
DAVIES DS, 1977, CLIN PHARMACOL THER, V21, P593
[7]   SERIAL CHANGES IN 24-HOUR CREATININE CLEARANCE DURING NORMAL MENSTRUAL CYCLES AND THE FIRST TRIMESTER OF PREGNANCY [J].
DAVISON, JM ;
NOBLE, MCB .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1981, 88 (01) :10-17
[8]  
DOLLERY SC, 1991, THERAPEUTIC DRUGS, pC305
[9]   COMPARISON OF THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF ORAL (CATAPRES) AND TRANSDERMAL (M-5041T) CLONIDINE IN HEALTHY-SUBJECTS [J].
FUJIMURA, A ;
EBIHARA, A ;
OHASHI, K ;
SHIGA, T ;
KUMAGAI, Y ;
NAKASHIMA, H ;
KOTEGAWA, T .
JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (03) :260-265
[10]  
HARTIKAINENSORRI AL, 1987, OBSTET GYNECOL, V69, P598